Monaco Asset Management SAM Sells 2,170,584 Shares of Gossamer Bio, Inc. $GOSS

Monaco Asset Management SAM reduced its stake in Gossamer Bio, Inc. (NASDAQ:GOSS) by 61.1% during the 3rd quarter, HoldingsChannel reports. The firm owned 1,379,416 shares of the company’s stock after selling 2,170,584 shares during the quarter. Gossamer Bio makes up approximately 0.2% of Monaco Asset Management SAM’s holdings, making the stock its 29th biggest holding. Monaco Asset Management SAM’s holdings in Gossamer Bio were worth $3,628,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. boosted its stake in Gossamer Bio by 5.2% in the 3rd quarter. Vanguard Group Inc. now owns 12,009,773 shares of the company’s stock valued at $31,586,000 after buying an additional 598,981 shares in the last quarter. Acadian Asset Management LLC boosted its stake in shares of Gossamer Bio by 12.4% in the 2nd quarter. Acadian Asset Management LLC now owns 7,146,022 shares of the company’s stock valued at $8,786,000 after purchasing an additional 787,909 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Gossamer Bio by 100.4% in the 2nd quarter. Geode Capital Management LLC now owns 4,555,080 shares of the company’s stock worth $5,604,000 after purchasing an additional 2,282,632 shares during the last quarter. Corient Private Wealth LLC increased its position in shares of Gossamer Bio by 8.9% during the 2nd quarter. Corient Private Wealth LLC now owns 3,693,683 shares of the company’s stock worth $4,543,000 after purchasing an additional 302,200 shares in the last quarter. Finally, MB Generational Wealth LLC bought a new position in Gossamer Bio during the 3rd quarter valued at about $3,721,000. Institutional investors own 81.23% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Barclays initiated coverage on shares of Gossamer Bio in a research note on Tuesday, January 27th. They issued an “overweight” rating and a $9.00 target price for the company. Wall Street Zen lowered Gossamer Bio from a “hold” rating to a “sell” rating in a research note on Friday, January 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gossamer Bio in a report on Thursday, January 22nd. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Gossamer Bio in a report on Thursday, January 22nd. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $8.60.

Gossamer Bio Stock Up 0.9%

Shares of GOSS opened at $2.13 on Friday. The stock’s fifty day simple moving average is $2.73 and its 200-day simple moving average is $2.68. The firm has a market capitalization of $493.01 million, a PE ratio of -3.09 and a beta of 1.93. Gossamer Bio, Inc. has a 12-month low of $0.76 and a 12-month high of $3.87.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.